Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models?
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD) has for decades been considered a pure motor disorder and its cardinal motor symptoms have been attributed to the loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta and to nigral Lewy body pathology. However, there has more recently been a shift in the conceptualization of the disease, and its pathological features have now been recognized as involving several other areas of the brain and indeed even outside the central nervous system. There are a corresponding variety of intrinsic non‐motor symptoms such as autonomic dysfunction, cognitive impairment, sleep disturbances and neuropsychiatric problems, which cannot be explained exclusively by nigral pathology. In this review, we will focus on cognitive impairment and affective symptoms in PD, and we will consider whether, and how, these deficits can best be modelled in rodent models of the disorder. As only a few of the non‐motor symptoms respond to standard DA replacement therapies, the quest for a broader therapeutic approach remains a major research effort, and success in this area in particular will be strongly dependent on appropriate rodent models. In addition, better understanding of the different models, as well as the advantages and disadvantages of the available behavioural tasks, will result in better tools for evaluating new treatment strategies for PD patients suffering from these neuropsychological symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 2×
“(mouse version of the forced-swim test; Steru et al., 1985) and acute injections of L-DOPA as well as a D2 agonist ameliorated this increase in immobility time (Mori et al.”
BackgroundNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 8×
“monoaminergic systems play a major role (Chaudhuri et al., 2006), as does extranigral a-synucleinopathy (Jellinger, 2011).”
BackgroundInfluentialAnimal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · cited 1×
“…and anxiety-related states in the rodents but, although much has been learned about the underlying neuropathology in the human disorder, no abnormality has proven sufficiently robust or consistent enough to be used as validation of rodent models (Kalueff et al., 2007; Nestler & Hyman, 2010).”
BackgroundA neostriatal habit learning system in humans
Knowlton, B. J., Mangels, J. A., & Squire, L. R. (1996) · Science · doi:10.1126/science.273.5280.1399 · Cited by 1,777
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579 · cited 1×
“Another major class of tests of depression-like behaviour are tests assessing anhedonia, one of the core symptoms of depression (Treadway & Zald, 2011).”
BackgroundMedial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat
Birrell, J. M., & Brown, V. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04320.2000 · Cited by 1,421 · cited 1×
“In this particular task, the rats are trained to dig for food by discriminating bowls that differ in both smell and digging media, and the number of trials to reach criterion is used a measure of flexible or inflexible behavior (Birrell & Brown, 2000; O’Neill & Brown, 2007).”
BackgroundStructure and function of declarative and nondeclarative memory systems
Squire, L. R., & Zola, S. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13515 · Cited by 1,327 · cited 1×
“The specific loss of memory in PD patients, especially in the last stage of the disease, presents as deficits in both spatial and non-spatial working memory, whereas the ability to form new episodic memories is preserved (Knowlton et al., 1996; Squire & Zola, 1996; Dubois & Pillon, 1997).”
BackgroundA systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050 · cited 1×
“As a consequence, we are now in a situation where non-motor symptoms associated with the disease, which are less well addressed by antiparkinsonian drugs, have a disproportionate impact on patients’ quality of life and progression of overall disability (Schrag, 2004; Hely et al., 2005).”
BackgroundCognitive profile of patients with newly diagnosed Parkinson disease
Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005) · Neurology · doi:10.1212/01.wnl.0000180516.69442.95 · Cited by 1,007 · cited 2×
“…usually appear at an older age, there is substantial evidence that cognitive dysfunction can be evident at earlier stages of the disease as well as in patients in whom overt signs of dementia are not present (Lees & Smith, 1983; Levin et al., 1989; Foltynie et al., 2004; Muslimovic et al., 2005).”
BackgroundCools, R. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.024 · Cited by 903
The orbitofrontal cortex: Neuronal activity in the behaving monkey
Thorpe, S. J., Rolls, E. T., & Maddison, S. (1983) · Experimental Brain Research · doi:10.1007/bf00235545 · Cited by 836 · cited 2×
“Deficits in reversal learning are classically associated with impairments in ventral (orbital) prefrontal cortex, and the associated projection areas in the striatum (Divac et al., 1967; Thorpe et al., 1983).”
Backgroundthe Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698 · cited 1×
“The validity of this staging has been vigorously debated (Halliday et al., 2006; Burke et al., 2008; Beach et al., 2009; Kingsbury et al., 2010), and has recently gained wider acceptance.”
BackgroundSAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
OPEN‐FIELD BEHAVIOR IN THE RAT: WHAT DOES IT MEAN?*
Denenberg, V. H. (1969) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1969.tb12983.x · Cited by 582
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502 · cited 4×
“…human a-synuclein have also been used to evaluate potential cognitive impairment: mice overexpressing wildtype asynuclein under the Thy1 promoter (Rockenstein et al., 2002) showed fewer alternations in a Y-maze and decreased novel-object recognition as well as deficits in reversal learning,…”
BackgroundInfluentialEndurance training enhances BDNF release from the human brain
Seifert, T., Brassard, P., Wissenberg, M., Rasmussen, P., Nordby, P., Stallknecht, B., Adser, H., Jakobsen, A. H., Pilegaard, H., Nielsen, H. B., et al. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00525.2009 · Cited by 502
Zhu, C.-B., Lindler, K. M., Owens, A. W., Daws, L. C., Blakely, R. D., & Hewlett, W. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.116 · Cited by 317
Deficits in Feeding Behavior after Intraventricular Injection of 6-Hydroxydopamine in Rats
Zigmond, M. J., & Stricker, E. M. (1972) · Science · doi:10.1126/science.177.4055.1211 · Cited by 296 · cited 1×
“On the other hand, extensive bilateral 6-OHDA lesions produce profound debility which require special husbandry (Ungerstedt, 1971; Zigmond & Stricker, 1972), especially if the toxin is administered into the lateral ventricles or the medial forebrain bundle to achieve maximal levels of depletion.”
BackgroundWhat's wrong with my mouse model?
Kalueff, A. V., Wheaton, M., & Murphy, D. L. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.023 · Cited by 285 · cited 2×
“states in the rodents but, although much has been learned about the underlying neuropathology in the human disorder, no abnormality has proven sufficiently robust or consistent enough to be used as validation of rodent models (Kalueff et al., 2007; Nestler & Hyman, 2010).”
BackgroundAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · cited 1×
“This indicates that medication enhancing noradrenergic neurotransmission would be beneficial in treating depression associated with PD; this has been corroborated in several (Lemke, 2002; Devos et al., 2008) but not all (Weintraub et al., 2010) recent studies.”
ResultThe lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235 · cited 2×
“This results in an inflammatory DA neurodegeneration to a variable extent depending on the dosing regimen (Dutta et al., 2008), but the accompanying motor impairment has not been reproducible between studies (Liu et al., 2008; Choi et al., 2009; Ariza et al., 2010).”
BackgroundCruise, K. E., Bucks, R. S., Loftus, A. M., Newton, R. U., Pegoraro, R., & Thomas, M. G. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01338.x · Cited by 229
Benefits of physical exercise on executive functions in older people with Parkinson's disease
Tanaka, K., Quadros, A. C. D., Santos, R. F., Stella, F., Gobbi, L. T. B., & Gobbi, S. (2009) · Brain and Cognition · doi:10.1016/j.bandc.2008.09.008 · Cited by 221
The prefrontal cortex and working memory: physiology and brain imaging
Passingham, D., & Sakai, K. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.03.003 · Cited by 207
Psychiatric aspects of Parkinson?s disease: An Update
Schrag, A. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0483-3 · Cited by 200 · cited 3×
“situation where non-motor symptoms associated with the disease, which are less well addressed by antiparkinsonian drugs, have a disproportionate impact on patients’ quality of life and progression of overall disability (Schrag, 2004; Hely et al., 2005).”
BackgroundLam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184 · cited 3×
“The time course of the impairments was paralleled by changes in extracellular levels of both DA and acetylcholine (Lam et al., 2011; Magen & Chesselet, 2011), providing possible mechanisms for the deficits seen in these tasks.”
BackgroundStriatal Neuroinflammation Promotes Parkinsonism in Rats
Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141 · cited 1×
“This results in an inflammatory DA neurodegeneration to a variable extent depending on the dosing regimen (Dutta et al., 2008), but the accompanying motor impairment has not been reproducible between studies (Liu et al., 2008; Choi et al., 2009; Ariza et al., 2010).”
BackgroundPothakos, K., Kurz, M. J., & Lau, Y.-S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-6 · Cited by 134
Gustafsson, G., Lira, C. M., Johansson, J., Wisén, A., Wohlfart, B., Ekman, R., & Westrin, Å. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.030 · Cited by 118 · cited 3×
“derived neurotrophic factor (Gustafsson et al., 2009; Seifert et al., 2010), which in itself has been shown to enhance cognition (Gustafsson et al.”
BackgroundResultGorton, L. M., Vuckovic, M. G., Vertelkina, N., Petzinger, G. M., Jakowec, M. W., & Wood, R. I. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.009 · Cited by 112 · cited 2×
“using the same dosing regimen of MPTP did not see any depressivelike behaviour assessed in terms of motivational change as decreased sucrose consumption (Vuckovic et al., 2008; Gorton et al., 2010).”
MethodResultEndotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits
Liu, Y., Qin, L., Wilson, B., Wu, X., Qian, L., Granholm, A.-C., Crews, F. T., & Hong, J.-S. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.02.014 · Cited by 84 · cited 1×
“This results in an inflammatory DA neurodegeneration to a variable extent depending on the dosing regimen (Dutta et al., 2008), but the accompanying motor impairment has not been reproducible between studies (Liu et al., 2008; Choi et al., 2009; Ariza et al., 2010).”
BackgroundDluzen, D. E., & Kreutzberg, J. D. (1993) · Brain Research · doi:10.1016/0006-8993(93)90860-p · Cited by 63
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Zameer, S., Najmi, A. K., Vohora, D., & Akhtar, M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1327200 · Cited by 74
Fifel, K., Piggins, H., & Deboer, T. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.02.005 · Cited by 30
Metadata
- Authors
- Lindgren, H. S., & Dunnett, S. B.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2012-06
- Volume
- 35
- Issue
- 12
- Pages
- 1894-1907
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W1960565658
- Cited by
- 57
- References
- 33
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.